lots of old discussion -- in this thread -- relating to this project and its' chances........
Thursday July 12, 6:30 pm Eastern Time
Press Release
SOURCE: Weiss & Yourman
Class Action Securities Lawsuit Filed Against Immune
Response Corp. And Agouron Pharmaceuticals
LOS ANGELES, July 12 /PRNewswire/ -- Weiss & Yourman announced today that it has filed a class action complaint on
behalf of all persons who acquired Immune Response Corp. (Nasdaq: IMNR - news) securities between May 17, 1999 and
July 6, 2001, inclusive (the ``Class Period''). The complaint charges Immune Response Corp. and Agouron Pharmaceuticals,
Inc. and their top officers with violations of federal securities laws.
Immune is a biopharmaceutical company developing immune-based therapies to induce specific T cell response for the
treatment of HIV, autoimmune diseases, gene therapy and cancer. Immune's major product is Remune, an injectable HIV-1
immunogen-based treatment designed to slow or stop the progression of HIV infections into AIDS. The company is also
developing and testing therapeutic products for other autoimmune conditions. Agouron Pharmaceuticals, Inc. was, until July 6,
2001, Immune's partner in developing Remune for commercial distribution and sale.
The complaint charges that Immune and Agouron withheld the results of Remune's major clinical trial, and instead hyped the
prospects of Remune, even though defendants knew during the Class Period that Remune had no effect upon people with HIV
and AIDS. The complaint further alleges defendants' false misrepresentations worked to artificially inflate the price of Immune
stock.
The Complaint alleges that as a result of the defendants' conduct, plaintiffs and other members of the class suffered damages.
Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Weiss & Yourman who
has significant experience and expertise in prosecuting class actions on behalf of investors and shareholders. If you are a
member of the class described above, you may, no later than September 10, 2001, move the court to serve as lead plaintiff, if
you so choose. In order to serve as lead plaintiff, however, you must meet certain legal requirements.
For further information please contact Weiss & Yourman (Los Angeles), +1-800-437-7918, Internet: www.wyca.com,
E-mail: info@wyca.com
SOURCE: Weiss & Yourman |
